We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Opiant Pharmaceuticals Inc | NASDAQ:OPNT | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 20.65 | 18.89 | 22.41 | 0 | 01:00:00 |
The Company’s management team is scheduled to host a conference call and webcast with slides at 4:30 p.m. ET on Tuesday, May 10, 2022. To access the call, please dial 1-877-407-0792 in the U.S. or 1-201-689-8263 outside the U.S. and provide the conference ID number: 13728852. To access the live webcast, please visit https://viavid.webcasts.com/starthere.jsp?ei=1542632&tp_key=dabaa0a667. Following the live webcast, an archived version of the call will be available on the website.
Tuesday May 10 @ 4:30 pm ET
Domestic: | 1-877-407-0792 |
International: | 1-201-689-8263 |
Conference ID: | 13728852 |
Webcast: | https://viavid.webcasts.com/starthere.jsp?ei=1542632&tp_key=dabaa0a667 |
About Opiant Pharmaceuticals, Inc.Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose.For more information visit: www.opiant.com.
For Media and Investor Inquiries:Ben Atkins, Opiant(310) 598-5410batkins@opiant.com
1 Year Opiant Pharmaceuticals Chart |
1 Month Opiant Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions